{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:47:50Z","timestamp":1790066870742,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Clinical Research Hospital Program","award":["PHRC 2008"],"award-info":[{"award-number":["PHRC 2008"]}]},{"name":"French Ministry of Health"},{"name":"Sanofi-Aventis France"},{"DOI":"10.13039\/501100004099","name":"Ligue Nationale Contre le Cancer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.ejca.2017.07.038","type":"journal-article","created":{"date-parts":[[2017,8,19]],"date-time":"2017-08-19T18:16:23Z","timestamp":1503166583000},"page":"239-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Health-related quality of life results from the PRODIGE 5\/ACCORD 17 randomised trial of FOLFOX versus fluorouracil\u2013cisplatin regimen in oesophageal cancer"],"prefix":"10.1016","volume":"84","author":[{"given":"C.","family":"Bascoul-Mollevi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gourgou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-P.","family":"Galais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-L.","family":"Raoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-Y.","family":"Douillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Adenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.-L.","family":"Etienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Juzyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bedenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Conroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.07.038_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2017.07.038_bib2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1470-2045(14)70028-2","article-title":"Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5\/ACCORD17): final results of a randomised, phase 2\/3 trial","volume":"15","author":"Conroy","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.07.038_bib3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/cncr.28382","article-title":"A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites","volume":"120","author":"Quinten","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2017.07.038_bib4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/gut.49.2.227","article-title":"The prognostic value of quality of life scores during treatment for oesophageal cancer","volume":"49","author":"Blazeby","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.ejca.2017.07.038_bib5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2036.2007.03589.x","article-title":"Factors predicting survival in patients with advanced oesophageal cancer: a prospective multicentre evaluation","volume":"27","author":"Bergquist","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejca.2017.07.038_bib6","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2004.08.154","article-title":"Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer\u2014pooled analysis from three multicenter, randomized, controlled trials using individual patient data","volume":"22","author":"Chau","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.07.038_bib7","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S1470-2045(09)70200-1","article-title":"Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials","volume":"10","author":"Quinten","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.07.038_bib8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2017.07.038_bib9","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/S0959-8049(03)00270-3","article-title":"Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer","volume":"39","author":"Blazeby","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2017.07.038_bib10","series-title":"EORTC QLQ-C30 scoring manual","author":"Fayers","year":"2001"},{"key":"10.1016\/j.ejca.2017.07.038_bib11","series-title":"EORTC QLQ-C30 reference values","author":"Fayers","year":"1998"},{"key":"10.1016\/j.ejca.2017.07.038_bib12","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2014.56.7974","article-title":"Statistical challenges in the analysis of health-related quality of life in cancer clinical trials","volume":"34","author":"Bonnetain","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.07.038_bib13","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E","article-title":"Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data","volume":"16","author":"Cnaan","year":"1997","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2017.07.038_bib14","series-title":"Design and analysis of quality of life studies in clinical trials","author":"Fairclough","year":"2002"},{"key":"10.1016\/j.ejca.2017.07.038_bib15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.07.038_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11136-013-0583-6","article-title":"Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?","volume":"24","author":"Anota","year":"2015","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ejca.2017.07.038_bib17","first-page":"2753","article-title":"Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma","volume":"46","author":"Bonnetain","year":"2010","journal-title":"Eur J Cancer\u00a0\u2013 Oxf Engl 1990"},{"key":"10.1016\/j.ejca.2017.07.038_bib18","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1634\/theoncologist.2011-0085","article-title":"Time to deterioration in quality of life score as a modality of longitudinal analysis in patients with breast cancer","volume":"16","author":"Hamidou","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2017.07.038_bib19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status. Ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ejca.2017.07.038_bib20","doi-asserted-by":"crossref","first-page":"v50","DOI":"10.1093\/annonc\/mdw329","article-title":"Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Lordick","year":"2016","journal-title":"Ann Oncol \u2013 Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2017.07.038_bib21","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/annonc\/mdl033","volume":"17","author":"Bonnetain","year":"2006","journal-title":"Ann Oncol \u2013 Off J Eur Soc Med Oncol ESMO"},{"key":"10.1016\/j.ejca.2017.07.038_bib22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/jjco\/hyt170","article-title":"Longitudinal assessments of quality of life and late toxicities before and after definitive chemoradiation for esophageal cancer","volume":"44","author":"Yamashita","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.07.038_bib23","first-page":"45","article-title":"Longitudinal quality-of-life analysis of RTOG 94-05 (Int 0123):a phase III trial of definitive chemoradiotherapy for esophageal cancer","volume":"4","author":"Kachnic","year":"2011","journal-title":"Gastrointest Cancer Res \u2013 GCR"},{"key":"10.1016\/j.ejca.2017.07.038_bib24","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/bjc.2015.258","article-title":"Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer","volume":"113","author":"Rees","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2017.07.038_bib25","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/jso.24378","article-title":"Activities of daily living and quality of life during treatment with neoadjuvant chemoradiotherapy and after surgery in patients with esophageal cancer: short-term decline of activities of daily living","volume":"114","author":"Haj Mohammad","year":"2016","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejca.2017.07.038_bib26","first-page":"2066","article-title":"Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach","volume":"43","author":"Lagergren","year":"2007","journal-title":"Eur J Cancer \u2013 Oxf Engl 1990"},{"key":"10.1016\/j.ejca.2017.07.038_bib27","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.ijrobp.2003.09.100","article-title":"Quality of life as a survival predictor for esophageal squamous cell carcinoma treated with radiotherapy","volume":"58","author":"Fang","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2017.07.038_bib28","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/annonc\/mdf063","article-title":"Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival","volume":"13","author":"Conroy","year":"2002","journal-title":"Ann Oncol \u2013 Off J Eur Soc Med Oncol ESMO"},{"key":"10.1016\/j.ejca.2017.07.038_bib29","first-page":"530","article-title":"Six-month postoperative quality of life predicts long-term survival after oesophageal cancer surgery","volume":"47","author":"Dj\u00e4rv","year":"2011","journal-title":"Eur J Cancer \u2013 Oxf Engl 1990"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917311589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917311589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T07:29:15Z","timestamp":1535441355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917311589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":29,"alternative-id":["S0959804917311589"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.07.038","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-related quality of life results from the PRODIGE 5\/ACCORD 17 randomised trial of FOLFOX versus fluorouracil\u2013cisplatin regimen in oesophageal cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.07.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}